Clinical Trials

1,096 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT03875235 2026-05-26

TOPAZ-1

810 enrolled 24 charts 1 FDA

Biliary Tract Neoplasms

NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

1,157 enrolled 1 FDA

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

789 enrolled 32 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02993523 2026-05-15

Viale-a

443 enrolled 14 charts 1 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04622319 2026-05-15

DESTINY-Breast05

1,600 enrolled 1 FDA

HER2-Positive Primary Breast Cancer

NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

644 enrolled 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

755 enrolled 28 charts 1 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03765918 2026-05-12

MK-3475-689

714 enrolled 90 charts 1 FDA

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT01946204 2026-05-11

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02489318 2026-05-11

TITAN

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT02970318 2026-05-11

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04497844 2026-05-11

AMPLITUDE

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT05243550 2026-05-11

ENVISION

240 enrolled 20 charts 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03274492 2026-05-08

POLARIX

1,000 enrolled 1 FDA

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03748641 2026-05-08

MAGNITUDE

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04487080 2026-05-08

MARIPOSA

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-05-08

PAPILLON

308 enrolled 12 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

776 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05083169 2026-05-08

MajesTEC-3

587 enrolled 1 FDA

Multiple Myeloma

NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT02032823 2026-05-06

OlympiA

1,837 enrolled 20 charts 1 FDA

Breast Neoplasms

NCT03456076 2026-05-05

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

257 enrolled 14 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-05-05

LAURA

216 enrolled 25 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05104866 2026-05-05

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03319667 2026-05-04

IMROZ

475 enrolled 1 FDA

Multiple Myeloma

NCT03504397 2026-05-04

Spotlight

565 enrolled 63 charts 1 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03907488 2026-05-04

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts 1 FDA

Lymphoid

Hodgkin Disease

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT02003222 2026-05-01

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

488 enrolled 13 charts 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02048813 2026-05-01

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

529 enrolled 12 charts 1 FDA

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03375320 2026-05-01

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT02486718 2026-04-30

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

1,280 enrolled 24 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04305496 2026-04-30

CAPItello-291

818 enrolled 19 charts 1 FDA

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT05198934 2026-04-27

CodeBreak300

160 enrolled 1 FDA

Colorectal Neoplasms

NCT03155997 2026-04-24

monarchE

5,637 enrolled 12 charts 2 FDA

Breast Neoplasms

NCT04666038 2026-04-24

BRUIN CLL-321

238 enrolled 17 charts 1 FDA

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04246047 2026-04-23

DREAMM 7

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT03043872 2026-04-22

CASPIAN

987 enrolled 42 charts 1 FDA

Small Cell Lung Carcinoma

NCT03395197 2026-04-22

TALAPRO-2

1,054 enrolled 21 charts 1 FDA

mCRPC

NCT01682083 2026-04-21

COMBI-AD

870 enrolled 15 charts 1 FDA

Dermatologic

Melanoma, Neoplasms

NCT02296125 2026-04-21

FLAURA

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT04083235 2026-04-20

NAPOLI 3

770 enrolled 13 charts 1 FDA

Metastatic Adenocarcinoma of the Pancreas

NCT04404283 2026-04-20

ECHELON-3

239 enrolled 1 FDA

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03653507 2026-04-17

GLOW

507 enrolled 65 charts 1 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03301220 2026-04-13

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT04099251 2026-04-09

CheckMate76K

790 enrolled 18 charts 1 FDA

Dermatologic

Melanoma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 1 FDA

Multiple Myeloma

NCT04039607 2026-04-06

CheckMate 9DW

732 enrolled 1 FDA

Carcinoma, Hepatocellular

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP